INVO Fertility, Inc. (IVF): Nasdaq/NYSE listing notice — INVO Bioscience receives Nasdaq deficiency notice for minimum bid price non-compliance

INVO Fertility, Inc.

On Jan 11, 2023, INVO received Nasdaq notice of non-compliance with minimum bid price of $1.00 per share.
Company has 180 days, until July 10, 2023, to regain compliance by closing at $1.00 for 10 consecutive business days.
If non-compliant after first period, Nasdaq may grant a second 180-day period if other listing standards are met.
Failure to cure could lead to delisting; company may appeal Nasdaq's determination.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 11, 2023, INVO Bioscience Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) listing qualifications group indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing under Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on T

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-001271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.